Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | CCR6 | P51684 | 1/20 | 0.42 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.42 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.42 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15753222 | 0.82 | ALDH1A1 (0.47) | ALDH1A1L3MBTL1TDP1MAPK1SLC6A2 | |
| SCHEMBL6252907 | 0.82 | ALDH1A1 (0.53) | ALDH1A1L3MBTL1TDP1MAPK1SLC6A2 | |
| SCHEMBL2321110 | 0.79 | ALDH1A1 (0.50) | ALDH1A1L3MBTL1TDP1MAPK1SLC6A2 | |
| SCHEMBL8419163 | 0.79 | ALDH1A1 (0.50) | ALDH1A1L3MBTL1TDP1MAPK1SLC6A2 | |
| SCHEMBL10666425 | 0.79 | ALDH1A1 (0.50) | ALDH1A1L3MBTL1TDP1MAPK1SLC6A2 | |
| SCHEMBL20243293 | 0.78 | ALDH1A1 (0.63) | ALDH1A1L3MBTL1TDP1MAPK1SLC6A2 | |
| SCHEMBL30263351 | 0.78 | ALDH1A1 (0.63) | ALDH1A1L3MBTL1TDP1MAPK1SLC6A2 | |
| SCHEMBL23651643 | 0.77 | ALDH1A1 (0.56) | ALDH1A1L3MBTL1TDP1MAPK1SLC6A2 | |
| SCHEMBL20921393 | 0.76 | ALDH1A1 (0.55) | ALDH1A1L3MBTL1TDP1MAPK1SLC6A2 | |
| Benzyl Dimethylcarbamate SCHEMBL5134244 | 0.74 | ALDH1A1 (0.62) | ALDH1A1L3MBTL1TDP1MAPK1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7834063-B2 | 4-[(Cyclopropylmethyl)(2-{[4-(1,1-dimethylethyl)phenyl]oxy}ethyl)amino]-2-(trifluoromethyl)benzonitrile; modulators of androgen, glucocorticoid, mineralocorticoid, and progesterone receptors; osteoporosis, muscle wasting,endometriosis, cardiovascular disease; breast, uterine cancer, prostatic hyperplasia | GLAXOSMITHKLINE LLC (US) | 2010-11-16 | — | — | US | disclosed |
| WO-2010028389-A1 | IMAGE-GUIDED ENERGY DEPOSITION FOR TARGETED DRUG DELIVERY | THE METHODIST HOSPITAL RESEARCH INSTITUTE (US) | 2010-03-11 | — | — | WO | disclosed |
| US-20080255124-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-16 | — | — | US | disclosed |
| EP-1809275-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-07-25 | — | — | EP | disclosed |
| WO-2006044707-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-04-27 | — | — | WO | disclosed |
| EP-1044967-B1 | 2-Pyridinylguanidine urokinase inhibitors | PFIZER (US) | 2004-08-11 | — | — | EP | disclosed |
| CN-1515550-A | Thrombosis resisting preparation | — | 2004-07-28 | — | — | CN | disclosed |
| US-20030203914-A1 | 2-Pyridinylguanidine urokinase inhibitors | DICKINSON ROGER PETER (GB) | 2003-10-30 | — | — | US | disclosed |
| US-20030199440-A1 | Composition for the treatment of damaged tissue | PFIZER INC. | 2003-10-23 | — | — | US | disclosed |
| US-6583162-B1 | 2-pyridinylguanidine urokinase inhibitors | WARNER-LAMBERT COMPANY | 2003-06-24 | — | — | US | disclosed |
| EP-1023268-A1 | ISOQUINOLINES AS UROKINASE INHIBITORS | Pfizer Limited (GB) | 2000-08-02 | — | — | EP | disclosed |
| WO-2000005214-A2 | ISOQUINOLINES AS UROKINASE INHIBITORS | PFIZER INC. (US) | 2000-02-03 | — | — | WO | disclosed |
| WO-1999067215-A1 | AMIDINO AND GUANIDINO AZETIDINONE TRYPTASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-12-29 | — | — | WO | disclosed |
| WO-1999020608-A1 | ISOQUINOLINES AS UROKINASE INHIBITORS | PFIZER LIMITED (GB) | 1999-04-29 | — | — | WO | disclosed |
| US-5691329-A | Compounds containing basic and acidic termini useful as fibrinogen receptor antagonists | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-11-25 | — | — | US | disclosed |
| EP-0802916-A1 | LOW MOLECULAR WEIGHT BICYCLIC THROMBIN INHIBITORS | BIOCHEM PHARMA INC (CA) | 1997-10-29 | — | — | EP | disclosed |
| CN-1147205-A | antithrombotic agent | LILLY CO ELI (US) | 1997-04-09 | — | — | CN | disclosed |
| WO-1996040741-A1 | PEPTIDYL HETEROCYCLES USEFUL IN THE TREATMENT OF THROMBIN RELATED DISORDERS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996040742-A1 | PEPTIDYL HETEROCYCLES USEFUL IN THE TREATMENT OF THROMBIN RELATEDDISORDERS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996040748-A1 | PEPTIDYL HETEROCYCLES USEFUL IN THE TREATMENT OF THROMBIN RELATED DISORDERS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199440-A1 | Composition for the treatment of damaged tissue | MMP1, SERPINE1, COL14A1 | ALDH1A1 2641/4885L3MBTL1 2500/4885TDP1 637/4885 |
| US-20080255124-A1 | Chemical Compounds | NR3C2, NR5A1, NR3C1 | ALDH1A1 1164/4885L3MBTL1 4755/4885TDP1 4649/4885 |
| US-20030203914-A1 | 2-Pyridinylguanidine urokinase inhibitors | PLAU, SERPINE1, REN | ALDH1A1 587/4885L3MBTL1 3920/4885TDP1 657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.